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Abstract
Background: Great variability in breast cancer (BC) treatment practices according to patient, tumour or
organisation of care characteristics has been reported but the relation between these factors is not well known. In
two French regions, we measured compliance with Clinical Practice Guidelines for non-metastatic BC care
management and identified factors associated with non-compliance at clinical and organisational levels.
Methods: Eligible patients had invasive unilateral BC without distant metastases and at least two contacts with
one of the two regional healthcare systems (2003-2004) in the first year after diagnosis. Medical data were
collected from patient medical records in all public and private hospitals (99 hospitals).
The care process was defined by 20 criteria: clinical decisions for treatment and therapeutic procedures. Each
criterion was classified according to level of compliance ("Compliant”, “Justifiable” and “Not Compliant”) and factors
of non-compliance were identified (mixed effect logistic regression).
Results: 926 women were included. Non-compliance with clinical decisions for treatment was associated with
older patient age (OR 2.1; 95%CI: 1.3-3.6) and region (OR 3.0; 95%CI: 1.2-7.4). Non-compliance with clinical decisions
for radiotherapy was associated with lymph node involvement or the presence of peritumoural vascular invasion
(OR 1.5; 95%CI: 1.01-2.3) and non-compliance with overall treatment (clinical decisions for treatment + therapeutic
procedures) was associated with the presence of positive lymph nodes (OR 2.0; 95%CI: 1.2-3.3), grade III versus
grade I (OR 2.9; 95%CI: 1.4-6.2), and one region of care versus another (OR 3.5; 95%CI: 1.7-7.1). Finally, heterogeneity
of compliance in overall treatment sequence was identified between local cancer units (p < 0.05).
Conclusion: This study provides interesting insights into factors of non-compliance in non-metastatic BC
management and could lead to quality care improvements.
Background
The treatment of breast cancer is complex and requires
multidisciplinary care [1,2]. To deal with this complexity
and reduce the number of inappropriate interventions,
government agencies and specialist societies have devel-
oped Clinical Practice Guidelines (CPGs). Nevertheless,
many studies [3-5] have highlighted a great variability of
practices in breast cancer treatment according to patient
or tumour characteristics, and the way care is organised.
Other studies in the literature emphasise organisational
factors as determinants of compliance with CPGs [6-11].
In 2003, all French regions began to develop local can-
cer units (LCUs) dedicated to cancer care. The aim at
t h i st i m ew a st oi m p r o v et h eq u a l i t yo fc a r eb ye n h a n -
cing the quality of therapeutic multidisciplinary commit-
tee discussions. These multidisciplinary committees base
their decisions on national or regional CPGs in order to
harmonise practices. Our objectives in this study were
firstly to measure the compliance with CPGs for the
management of non-metastatic breast cancer care and
secondly to identify factors associated with non-compli-
ance at a clinical and organisational level (LCU).
Methods
Study design and population selection
Eligible patients had a pathological diagnosis of invasive
unilateral breast cancer without distant metastases (from
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one of the two regional healthcare systems between diag-
nosis and their first year of follow-up, no previous malig-
nancy, and provided written informed consent. These
eligible patients were reported by public and private hos-
pitals in the two regions (additional file 1: 99 eligible hos-
pitals: 13% with less than 11 BC surgeries per year and
51% with more than 50). All oncologists in both regions
reported every patient with a first diagnosis of invasive
non-metastatic breast cancer. Following this, a letter
explaining the aims of the study was sent to each patient,
together with a consent form and a questionnaire collect-
ing personal information. Once the consent form had
been received, medical data was collected from the
patient’s medical record. The logistics of data collection
were carried out by a experienced research team specifi-
cally dedicated to the project (research assistants and
research practitioners). Full details of the present design
were published earlier [12,13]. Clinical data covered the
care process from diagnosis to the last sequence of treat-
ment (follow-up was excluded). The care process was
divided into six potential steps: initial and complemen-
tary surgery, breast or chest radiotherapy, lymph node
radiotherapy, chemotherapy, and hormone therapy. This
study was approved by the ethics committee.
Evaluation of compliance with practice guidelines
We categorised the available non-metastatic BC manage-
ment pathways from French national CPGs (additional
file 2) into 20 criteria (Additional file 3). These criteria
were used to assess compliance with the care process for
each patient according to the six steps defined. Each cri-
terion was classified into three levels of compliance: (C)
compliance with CPGs; (J) justifiable non-compliance,
i.e., not strictly compliant but documented justification
due to the patient’s general status, preference or a change
during the course of care management (for example, che-
motherapy interruption related to adverse effects) or
other factors; (NC) non-compliance with CPGs and no
justification available in the patient’sm e d i c a lr e c o r d .F o r
each criterion, the conditions needed to define three-
level compliance were defined by a specific questionnaire
sent to the relevant experts (surgeon, pathologist, radiol-
ogist, chemotherapist and radiation oncologist); more-
over, these definitions were agreed upon by each expert.
For example, we defined the type of breast and lymph
node surgery recommended for different tumour sizes
(< 1 cm, 1-3 cm, and >3 cm). Finally, the entire expert
group reached a consensus on the description of criteria
with particular attention to the justifiable category.
Study variables
To measure the appropriateness of medical decisions,
we also defined compliance with criteria which included
therapeutic decisions as opposed to diagnostic or orga-
nisational elements (criteria 1, 2, 6, 15, 18, 20). More-
over, we studied both the clinical decisions for
treatment and therapeutic procedures of the least com-
pliant therapeutic steps (criteria 6-14). In addition to
assessing the 20 criteria, overall treatment compliance
(clinical decisions for treatment and therapeutic proce-
dures) with CPGs was determined for each patient. This
depended on the compliance with criteria 1-20 of clini-
cal care. Because we modelled the probability of non-
compliance, the overall treatment sequence compliance
was coded ‘0’ if all therapeutic clinical decisions for
treatment and therapeutic procedures were compliant
(C) or justifiable (J), and ‘1’ if at least one of these was
not compliant with standards (NC).
Explanatory variables were selected from the litera-
ture review and related to the patient and her social
status [1,14,15], to the tumour [6,7,15-18] and to the
healthcare system [1,6-8]. Patients’ characteristics were
analysed by age (< 50, 50-69, ≥70), educational level
(less than high-school diploma, at least high-school
diploma), cohabitation status (living alone, living with
other(s)), menopausal status (pre- or postmenopausal).
Tumour characteristics were analysed by localisation
(central, medial/lateral, several quadrants), nodal
status (negative, positive), histological tumour size
(≤10 mm, 11-30 mm, >30 mm), hormonal receptor sta-
tus (oestrogen or progesterone receptors positive, both
receptors negative), lymph node and peritumoural vas-
cular invasion (presence/absence), histological grade
(I, II, III). Tumour staging was recorded according to
the American Joint Committee on Cancer classification
[19]. Variables related to the healthcare system were sector
of care (public, private, both), surgical hospital status
(teaching, non-teaching) and region where patients under-
went surgery. Given that variations in care across practices
has been documented previously in France [20], we sus-
pected that non-compliance could vary across the LCUs
(15 Units) and thus considered this variable when evaluat-
ing non-compliance with CPGs.
Statistical analysis
We examined factors associated with non-compliance
with CPGs. Aside from the LCU, all variables were first
fitted in univariate logistic regression models. Variables
significant in the univariate analyses (p < 0.20), as well
as relevant clinical variables, were then fitted in a classi-
cal multivariate logistic model [21]. This process was
independently repeated for each outcome variable: non-
compliance regarding 1) clinical decision for treatment,
2) radiotherapy, 3) overall treatment sequence.
As the compliance of many patients at the same LCU
could depend on local management practices, we
expected data clustering to occur at the level of the
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ing a random effect in our classical multivariate model
[22]. By doing so, the LCUs were assumed to give rise
to another source of random variation in addition to the
residual variation left unexplained by the fixed-effect
variables. The resulting mixed-effect model accommo-
dated for correlations within LCUs, or similarly, hetero-
geneity of non-compliance between LCUs. We tested
this heterogeneity of practices across LCUs by compar-
ing the mixed-effect model to the initial classical logistic
model using the likelihood ratio test (LRT) [21]. We
reported odds ratios (OR) with their 95% confidence
intervals (95% CI) and performed all statistical analyses
with the SAS 8.2 software.
Results
Population
Informed consent was obtained from 955 of the 1416
eligible patients; other patients were refusals (193, 13%)
or non-response (269, 18%). Twenty nine patients were
excluded from the analysis for the following reasons:
other non-breast cancer (n = 1), bilateral tumour (n = 21)
or medical record not available (n = 7). Mean patient age
was 58.5 years (range: 24-89). Patients, tumour character-
istics and care sector itinerary are presented in Table 1.
All but nine patients underwent surgery: 688 (75%) had
conservative surgery, 226 (25%) had mastectomy and
three patients had lymph node surgery without breast
surgery. Sentinel node biopsy was performed in 214
patients (26%) and lymph node surgery in 842 (91%). A
breast or chest radiotherapy was used for 902 patients
(97%) and all but three procedures of conservative sur-
gery were followed by radiotherapy. Lymph node radio-
therapy was performed on axillary lymph nodes in 52
(6%) patients, on internal mammary lymph nodes in 507
(55%) and on supraclavicular lymph nodes in 520 (56%)
patients. Chemotherapy was administered to 444 (48%)
patients, among whom 21% participated in a clinical trial,
and 670 (72%) patients received hormonal therapy,
including nine who participated in a clinical trial. Finally,
four of ten patients were managed in both the private
and public sector, and surgery was mostly performed in
non-teaching hospitals.
Compliance by care management step
The surgical procedures were compliant to CPGs (cri-
teria 1-5) for 65% (604) of patients; the radiotherapy
procedures (criteria 6-14) for 48% (442); chemotherapy
procedures (criteria 15-17) for 73% (679); hormonal
therapy procedures (criteria 18-19) for 88% (816); and
the multidisciplinary committee discussion (criterion 20)
for 59% (546) of patients. Compliance with treatment cri-
teria in each step showed that the time to radiotherapy
Table 1 Description of breast cancer population (926
patients)
Characteristics N (%)
Age (years)
< 50 250 (27)
50-69 468 (51)
≥ 70 208 (22)
Educational level
Less than baccalaureate (secondary-school diploma) 627 (71)
Baccalaureate or higher 262 (29)
Live alone
No 738 (79)
Yes 194 (21)
Tumour localisation
Central 47 (5)
Several quadrants 247 (27)
Medial or lateral 603 (68)
Stage AJCC/UICC*
Stage 0 and 1 447 (49)
Stage 2 332 (36)
Stage 3 137 (15)
Menopausal status
Postmenopausal 590 (67)
Premenopausal 284 (33)
Nodal status
Negative 566 (63)
Positive 336 (37)
Histological size (mm)
≤ 10 250 (29)
10-30 544 (62)
> 30 76 (9)
Hormonal receptor status
At least one receptor positive 742 (81)
Two receptors negative 170 (19)
Peritumoural vascular invasion
No 385 (42)
Yes 229 (25)
Unknown 312 (34)
Histological grade
Grade I 211 (24)
Grade II 422 (48)
Grade III 254 (72)
Care sector itinerary
Public 333 (36)
Private 231 (25)
Both (public and private) 362 (39)
Status of surgical hospital
Teaching 223 (24)
Not teaching 703 (76)
Region of surgery
Region 1 558 (63)
Region 2 326 (37)
*AJCC: American Joint Committee on Cancer.
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patients (1%) had no surgery. For 107 (12%) patients, no
indication of the tumour size was found, so compliance
of the initial surgical decision was coded as ‘J’. Conserva-
tive surgery showed a higher rate of compliance than
mastectomy (72% vs 47%). Clinical decisions for radio-
therapy mostly complied with CGPs following conserva-
tive surgery (99%) and mastectomy (86%). When
chemoterapy was indicated, the vast majority of patients
received it (99%), but chemotherapy was also given to
29% of patients who had no clinical decision according to
the criterion. Hormonal therapy was given to 3% of
patients for whom receptors were negative and not given
to 11% of patients for whom receptors were positive.
Factors associated with treatment compliance
With regard to clinical decisions for treatment,t h er a t e
of non-compliance with CPGs was 71% (657 patients).
Variables selected from the univariate analyses and first
included in a multivariate fixed-effect model were: age
(p = 0.001), education level (p = 0.03), cohabitation sta-
tus (p = 0.06), stage (p = 0.18), hormonal status (p =
0.06), care sector (p < 0.0001), teaching status of surgi-
cal hospital (p = 0.0004) and region where patients
underwent surgery (p < 0.0001). After fitting the multi-
variate fixed-effect model, three factors were associated
positively with non-compliance (p < 0.05): age, status of
surgical hospital, and region where patients underwent
surgery. Introducing the LCUs as a random effect
appeared to decrease the residual variability (LRT, p <
0.05), which again indicated heterogeneity in compliance
with clinical decisions for treatment,a c r o s sL C U sa n d
emphasised the need to keep this variable in our model.
The mixed-effect model suggested that compared to
patients under 50 years of age, patients over 70 years
had a two-fold risk of non-compliant care management
(OR = 2.1; 95% CI, 1.3-3.6). Similarly, there was a three-
fold increase in the risk of non-compliance for one
region compared to the second one (OR = 3.0; 95% CI,
1.2-7.4). Finally, note that although the teaching status
of the surgical hospital had a significant effect in the
fixed-effect model (p = 0.0004), it was no longer signifi-
cant in the mixed-effect model (p = 0.12).
Of all the therapeutic steps considered, radiotherapy
was the least compliant step: we observed at least one
non-compliant clinical decision for radiotherapy or
radiotherapy procedure criterion for 484 patients (52%).
Variables selected from the univariate analyses and first
included in a multivariate fixed-effect model were:
tumour localisation (p = 0.036), nodal status (p = 0.009),
histological size (p = 0.018), hormonal receptor status
(p = 0.007), peritumoural vascular invasion (p = 0.001),
grade (p = 0.015), and region where patients underwent
surgery (p = 0.04). Peritumoural vascular invasion, histo-
logical grade and region were positively associated with
non-compliance in the multivariate fixed-effect model.
Including the LCU as a random effect decreased the resi-
dual variability (LRT, p < 0.05), suggesting the presence
of heterogeneity of compliance in radiotherapy across
LCUs. Based on this mixed-effect model, only the pre-
sence of peritumoural vascular invasion remained signifi-
cant at the 5% level, and it was associated with 1.5-fold
risk of non-compliance (OR = 1.5; 95% CI, 1.01-2.3).
Table 2 Criteria by step of breast cancer care according
to the presence of compliance with Clinical Practices
Guidelines (C), justifiable non-compliance (J) or non-
compliance (NC) (926 patients)
Compliant Justifiable Non-
compliant
Total*
N (%) N (%) N (%)
Surgery
Clinical decision
Initial 672 (73) 229 (25) 25 (3) 926
Complementary 712 (77) 66 (7) 148 (16) 926
Procedure
≥ 10 lymph
nodes
602 (71) 117 (14) 123 (15) 842
Complete
resection
716 (78) _ _ 198 (22) 914
Surgical staging 903 (99) _ _ 11 (1) 914
Radiotherapy
Clinical decision
Breast or chest 892 (96) 0 (0) 34 (4) 926
Axillary 880 (95) 2 (0) 44 (5) 926
Internal
mammary
625 (67) 196 (22) 105 (11) 926
Supraclavicular 627 (68) 165 (18) 134 (14) 926
Procedure
Breast or chest 696 (77) 165 (18) 41 (5) 902
Axillary 38 (73) 8 (15) 6 (11) 52
Internal
mammary
376 (74) 111 (22) 20 (4) 507
Supraclavicular 382 (73) 113 (22) 25 (5) 520
Time to
radiotherapy
568 (62) 30 (3) 313 (34) 911
Chemotherapy
Clinical decision 550 (59) 235 (25) 141 (15) 926
Procedure
Protocols/cycles 373 (84) 15 (3) 56 (13) 444
Time to
chemotherapy
355 (80) 33 (7) 56 (13) 444
Hormonal therapy
Clinical decision 822 (89) 19 (2) 85 (9) 926
Procedure 616 (92) 29 (4) 25 (4) 670
Multidisciplinary meeting 526 (57) 20 (2) 380 (41) 926
* All patients were concerned by clinical decision criteria. With regard to
therapeutic procedure criteria, only patients whose clinical decision gave rise
to a therapeutic procedure were concerned.
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sion treatment and therapeutic procedure), at least one
criterion was not completely compliant with CPGs in
88% of 926 patients. Variables selected from the uni-
variate analyses and first included in the multivariate
fixed-effect model were: care sector (public or private)
(p < 0.0001), region where patients underwent surgery
(p < 0.0001), grade (p = 0.0002), stage (p = 0.0003),
nodal status (p = 0.0004), hormonal receptor status
(p = 0.01), peritumoural vascular invasion (p = 0.02),
histological size (p = 0.02), age (p = 0.06), educational
level (p = 0.06), cohabitation status (p = 0.14), and
teaching status of surgical hospital (p = 0.20). After
adjustment, three factors were positively associated
with non-compliance in the overall treatment sequence
in the multivariate model (p < 0.05, Table 3): nodal
status, histological grade, and region where patients
underwent surgery. Finally, introducing the LCU as a
random effect significantly decreased the residual
variability (LRT, p < 0.05), suggesting the presence of
heterogeneity of compliance in overall treatment
sequence across LCUs and reinforcing the need to
keep this variable in our model. Estimates from this
mixed-effect model suggested that, compared to
patients without lymph node metastasis, lymph node-
positive patients had a two-fold risk of non-compliance
(OR = 2.0; 95% CI, 1.2-3.3); patients with grade III
tumours had a three-fold risk of non-compliance com-
pared to patients with grade I (OR = 2.9; 95% CI, 1.4-
6.2); and patients whose surgery was performed in one
of the two regions had a 3.5-fold higher risk than the
other region (OR = 3.5; 95% CI, 1.7 -7.1).
Discussion
This study showed three main results: BC compliance,
factors associated with non-compliance and a multidisci-
plinary and multi-hospital organisation to BC care
which explains the variability in BC practices. Together
these results can be used to enhance BC care.
The first results of our study concern BC care compli-
ance that ranged from 88% for hormonal therapy to
48% for radiotherapy, essentially due to the non respect
of delay to radiotherapy. With respect to overall treat-
ment sequences, the management of non-metastatic
breast cancer was fully compliant (20 criteria) with
CPGs in only 12% of cases. This proportion increased to
29% when only clinical decisions for treatment steps
were considered. To our knowledge, this is the first time
that results of overall BC therapeutic care with details
on procedures and clinical decision sequences have been
reported in a large BC population. Indeed, most recent
publications have only focused on single therapeutic
care management step (surgery, radiotherapy or che-
motherapy) according to BC stage and most do not
provide details on overall compliance with clinical deci-
sions. International studies [1,3,6,17,23-26] have found a
higher compliance rate for performing a biopsy before
surgery, radiotherapy and chemotherapy, and a lower
rate for performing radiotherapy after conservative
breast surgery and hormonal therapy. However, caution
is required with such comparisons because many studies
d i dn o ta c c u r a t e l ye x p l a i nt h ec o m p l i a n c ec r i t e r i at h e y
used. Two other French regional studies have compared
breast cancer management with CPG recommendations
and found approximately similar results. The first study
(100 patients by audits of medical records) [27] reported
the same proportion of non-compliance for clinical deci-
sion for lymph node surgery and for clinical decision for
radiotherapy. The second [5] observed strict compliance
with clinical decision for treatment in 1995: 92-96% for
surgery, 71-85% for chemotherapy, 72-93% for radio-
therapy and 83-94% for hormonal therapy. Our results
show similar or higher levels of compliance.
We also reported in our study factors related to BC
non-compliance. Older age and region were factors to
explain non-compliant clinical decisions for treatment
and confirm then results reported previously [3,15].
Concerning radiotherapy, the least compliant step,
non-compliance was associated with three prognostic
factors (nodal status, peritumoural vascular invasion
and histological grade) and the region of surgical treat-
ment. Finally, we showed an association between over-
a l ln o n - c o m p l i a n c ea n dt h ep r e s e n c eo fp o s i t i v el y m p h
nodes, histological grade III and region. Lymph node
involvement and histological grade are known prog-
nostic factors for breast cancer recurrence and survi-
val. These two clinical characteristics are part of CGPs
for breast cancer management and are considered, for
example, in making decisions regarding the need for
chemotherapy or radiotherapy. Our findings emphasise
their impact on overall non-compliance. Concerning
the region of BC treatment, a factor associated with
non-compliance, the region with a higher compliance
rate had already implemented breast cancer CPGs
(2004) by local specialist involvement in regional
guidelines at the time of the study. This implementa-
tion could be explained partially by the regional differ-
ences. But some disparity for care accessibility
(equipment or personnel resources) between the two
regions could explain part of these differences, as
reported by others [28]. The more recent publications
of factors related to the implementation of CGPs
[9-11,29,30] showed that patient factors, such as
comorbidities or very short life expectancy, reduce the
chance that guidelines are followed because they do
not encourage the physician to prescribe aggressive
therapy. Physician factors related to implementation
could be seniority, lack of awareness and limited
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tors such as limited time, work pressure and limited
support from peers have been described as barriers to
change. Our results showed finally a variability in com-
pliance with CPGs that may be due to the LCU. This
discrepancy in practices underlines the need to
enhance cancer care coordination and multidisciplinary
care at a local level, so that variation in care can be
reduced. Whether we modelled the non-compliance of
practices within the overall treatment sequence, with
regard to clinical decision for treatment, or with regard
to radiotherapy only, introducing the LCU as a random
variable significantly decreased residual variability.
These results confirm the presence of heterogeneity
across LCUs, or equivalently, the presence of correla-
tion within LCUs.
This study has a number of strengths and limitations.
Firstly, concerning the population, data collection and
definition of non-compliance, we cannot exclude a
population selection bias since a proportion of women
w e r en o ti n c l u d e d( r e f u s a lo rn o nr e s p o n s e )a n dw e
included probably more patients from hospitals with
high volumes (but regional data are available for com-
parison concerning all stages of cancer, metastatic and
non-metastatic BC). We proposed 20 criteria that distin-
guish clinical decisions for treatment from the
Table 3 Multivariate analyses for non-compliance of overall treatment sequence, therapeutic indications and
radiotherapy (926 patients)
Compliance (C/J) Non-compliance (NC) Logistic model Logistic mixed model
Variables No of patients % No of patients % OR 95% CI OR 95% CI
Clinical decisions for treatment (n = 856)
Age (years)
< 50 82 (33) 168 (67)
50 - 69 148 (32) 320 (68) 1.0 0.7-1.4 1.1 0.8-1.7
> 70 39 (19) 169 (81) 1.9 1.2-3.0 2.1 1.3-3.6
Surgical hospital
Teaching 86 (39) 137 (61)
Not teaching 183 (26) 520 (74) 1.4 1.02-2.0 1.7 0.9-3.3
Region
Region 1 199 (36) 359 (64)
Region 2 62 (19) 264 (81) 2.1 1.5-3.0 3.0 1.2-7.4
Radiotherapy (clinical decision and procedure) (n = 817)
Peritumoural vascular invasion
No 211 (55) 174 (45)
Yes 97 (42) 132 (58) 1.6 1.1-2.3 1.5 1.01-2.3
Unknown 134 (43) 178 (57) 1.4 0.99-1.9 1.3 0.9-1.9
Histological grade
Grade I 113 (54) 98 (46)
Grade II 211 (50) 211 (50) 1.0 0.7-1.4 1.0 0.7-1.5
Grade III 104 (41) 150 (59) 1.6 1.1-2.3 1.5 0.97-2.4
Region
Region 1 285 (51) 273 (49)
Region 2 143 (44) 183 (56) 1.5 1.1-2.0 1.3 0.7-2.3
Overall treatment sequence (n = 805)
Nodal status
Negative 88 (16) 478 (84)
Positive 26 (8) 310 (92) 2.0 1.2-3.2 2.0 1.2-3.3
Histological grade
Grade I 33 (16) 178 (84)
Grade II 65 (15) 357 (85) 0.9 0.5-1.4 0.9 0.5-1.5
Grade III 15 (6) 239 (94) 2.9 1.5-5.7 2.9 1.4-6.2
Region
Region 1 90 (16) 468 (84)
Region 2 22 (7) 304 (93) 3.5 1.9-5.2 3.5 1.7-7.1
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compliance is necessary to understand better the com-
plexity of the care process, particularly in BC manage-
ment. A recent synthesis [9] showed that the complexity
of CPGs can be one factor of non-compliance and could
so explain a low rate of overall compliance. Our results
showed that compliance was lowest for radiotherapy
lead time and multidisciplinary approach. Long radio-
therapy lead times have already been reported in Italy
[31] and in a critical review of the literature [28] and
are partly due to lack of equipment or human resources
[32]. The French national Cancer Plan has attempted to
respond to this shortcoming [33]. Patient management
in multidisciplinary meetings is recommended for every
cancer patient, but this recommendation was too recent
(2003) at the date of our study and may explain the
relatively low compliance rate of 57%.
We grouped compliance (C) and justifiable non-
compliance (J) in the same category, particurlaly to
ensure the homogeneity of the data within the non-
compliance category (NC). Another statistical choice
could be an analysis with three levels of compliance
(a polychotomous regression). However, our primary
interest was to specifically assess determinants of non-
compliance/non conformity to CPGs, without distin-
guishing compliant and justifiable decisions, which we
considered as equivalent. Indeed, from a practical point
of view, it is best to specifically target those factors asso-
ciated with non-compliance so that actions can be under-
taken. In view of these objectives, logistic regression
using two levels was the optimal modelling approach.
Another potential limitation of our results was the
availablity of data in medical records to explain non-
compliance and our choice of professionals or organisa-
tional factors. We could not collect all data on every
professional (for instance, experience or age) but BC
management is multidisciplinary and several specialists
are involved in medical decisions at each BC manage-
ment step. Concerning organisational factors, we cannot
relate overall compliance to the hospital’sv o l u m es i n c e
the breast cancer care steps are often in different hospi-
tals (surgery in one hospital and radiotherapy in
a n o t h e r . . . )a n dt h e s eh o s p i t a l sm a yh a v ed i f f e r e n t
volumes. It therefore seemed that the most interesting
data was the LCU. However, we use hospital volume in
a recent publication focused on surgery step [12].
We must underline several points concerning the
interpretation of our results. Firstly, a negative impact
on outcomes of high non-compliance rate with CPGs
for non-metastatic breast cancer management should be
interpreted carefully. Each criterion received the same
weight whatever its prognostic value and some patients
had more non-compliant criteria than others. However,
more than two thirds of the patients had fewer than
three non-compliant criteria. A specific consensus [34]
amongst local breast cancer experts will be required to
develop and apply criteria integrating weights according
to prognostic impact. This definition of non-compliance
of care management could increase heterogeneity
between LCUs, even though variations in practice
between LCUs are not surprising since similar variations
have been reported for larger institutions [35]. In addi-
tion, it should be noted that service improvements for
local and regional cancer care organisations (including
implementation of LCU) was probably too recent at the
date of this study to have an homogeneous impact on
medical practices. It would be useful to reproduce this
study in another cohort of patients to ascertain if com-
pliance with CPGs has improved over time. Currently,
the implementation of the regional guidelines cannot be
used as the only factor to explain a better compliance in
one region. Indeed, it is well known that adherence with
these guidelines depends on many other factors [9-11]
such as guideline, professional, patient and environmen-
tal characteristics. Our study was implemented between
2003 and 2004, and we studied compliance based on
CPGs implemented at this time and in these areas.
Secondly, in the presence of heterogeneity across
LCUs, it is important to rely on an appropriate statisti-
cal model; otherwise misleading conclusions can be
derived. We relied on a mixed-effect model which
allowed us to account for the presence of clusters.
Other approaches have been suggested to test for the
heterogeneity of responses in the context of binary vari-
ables, such as the estimation of the median odds ratio
as suggested recently [36]. Applying this method did not
modify our initial conclusions with respect to heteroge-
neity across practices.
Finally, this study provides interesting insights into
factors of non-compliance in non-metastatic BC man-
agement and could lead to quality care improvements. It
must be followed by feedback to LCUs and to the regio-
nal organisation. Feedback is considered as one of the
most efficient methods for improving the application of
CPGs [37]. Repeated studies will be required to confirm
the likely impact of regional service improvement initia-
tives over time.
Conclusion
Our findings emphasise also the need for the national
scientific and local cancer care organisations to provide
further clarification of BC clinical practice guidelines
(which may currently be too complex for a complete
implementation in local cancer units). For decision
makers and national health care authorities, priorities
need to be defined in the quality of cancer care regard-
ing care coordination and local cancer units as well as
their equipment and personnel resources.
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Additional file 1: Breast cancer surgery volume per year according
to number hospitals and patients in REPERES study (data available
from a database managed by the French Ministry of Health).
Distribution of patients according to four categories of volume of breast
cancer surgery hospital: 10 and less/11-50/51-150/151 and over (data of
volume surgery were provided by administrative data, years 2003 and
2004).
Additional file 2: National and international Clinical Practice
Guidelines for the management of non-metastatic breast cancer
published before 2004 (non exhaustive list of Guidelines, except in
France). a non exhaustive list of national and international Clinical
Practice Guidelines for the management of non-metastatic breast cancer.
Additional file 3: Definition of compliance by criterion in cancer
care process for non-metastatic invasive breast cancer according to:
compliant (C), justifiable (J), not compliant (NC). List of 20 criteria of
Breast Cancer management pathways. These criteria were used to assess
compliance with the care process for each patient according to the six
steps defined. Each criterion was classified into three levels of
compliance: (C) compliance with CPGs; (J) justifiable non-compliance, i.e.,
not strictly compliant but documented justification due to the patient’s
general status, preference or a change during the course of care
management (for example, chemotherapy interruption related to adverse
effects) or other factors; (NC) non-compliance with Clinical Practice
Guidelines and no justification available in the patient’s medical record.
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